Effect of beraprost sodium, a stable prostacyclin analogue, on pulmonary thromboembolism in mice.
Ueno
Y
Y
Toray Industries, Inc., Basic Research Laboratories, Kanagawa, Japan.
Kawashima
A
A
Koike
H
H
Nishio
S
S
D000284:Administration, Oral; D000527:Alprostadil / Q000627:therapeutic use; D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use; D003094:Collagen / Q000633:toxicity; D004110:Diltiazem / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004837:Epinephrine / Q000633:toxicity; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use; D006830:Hydralazine / Q000627:therapeutic use; D007275:Injections, Intravenous; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009543:Nifedipine / Q000627:therapeutic use; D009599:Nitroprusside / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000139:chemically induced / Q000517:prevention & control*; D013482:Superoxide Dismutase / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D001643:Bridged Bicyclo Compounds; D005229:Fatty Acids, Monounsaturated; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; C056566:S 145; D009599:Nitroprusside; D006830:Hydralazine; C048081:beraprost; D006493:Heparin; D003094:Collagen; D011464:Epoprostenol; D013482:Superoxide Dismutase; D004110:Diltiazem; D000527:Alprostadil; D009543:Nifedipine; D007548:Isosorbide Dinitrate; D001241:Aspirin; D004837:Epinephrine